Rigel Pharmaceuticals Inc. Common Stock (RIGL)
Stock · NASDAQ · Health Care
$46.01as of 10/16/2026
Price chart
Active signals
RIGL Signal Track Record
How signals performed across all stocks →What RIGL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +2.4% | 54% | September 18, 2026 |
| Bollinger Band Breakout | 26 | +2.4% | 62% | August 19, 2026 |
| Bollinger Band BreakdownActive now | 19 | -3.3% | 42% | May 6, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +5.2% | 58% | July 14, 2025 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 172
- Website
- www.rigel.com/
Fundamentals
- 1-day range
- $45.7$47.58
- Market cap
- $732.62M
- P/E (trailing)
- 2.76
- P/E (forward)
- 9.26
- EPS (trailing)
- $16.04
- Dividend yield
- —
- Beta
- 1.26
- Avg. volume
- 276.0K
How Rigel Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Rigel Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
- CTMXCytomX Therapeutics Inc. Common Stock$2.28▼ 5.39%Market cap $733.66MP/E —$2.2$8.21
- CYRXCryoPort Inc. Common Stock$16.84▼ 1.35%Market cap $741.42MP/E —$7.61$18.36
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $2.28 | ▼ 5.39% | $2.2$8.21 |
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.84 | ▼ 1.35% | $7.61$18.36 |
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - SlideshowSeekingAlpha · 9/15/2026
- Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsightYahoo · 9/15/2026
- Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - SlideshowSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Schorno Dean L · September 2, 2026 · Option Exercise1.3K @ $24.2
- Schorno Dean L · September 2, 2026 · Option Exercise2.0K @ $24.2
- Schorno Dean L · September 2, 2026 · Option Exercise620 @ $18.7
- Schorno Dean L · September 2, 2026 · Option Exercise694 @ $12.7
- Schorno Dean L · September 1, 2026 · Tax Withholding928 @ $47.5
- Santos David A · September 1, 2026 · Tax Withholding874 @ $47.5
- RODRIGUEZ RAUL R · September 1, 2026 · Tax Withholding2.4K @ $47.5
- Furey Raymond J. · September 1, 2026 · Tax Withholding877 @ $47.5
- HANNAH ALISON L. · July 8, 2026 · Grant24.4K
- Ali-Jackson Kamil · June 22, 2026 · Sale2.5K @ $35
- Rojkjaer Lisa · June 17, 2026 · Grant7.4K
- Rojkjaer Lisa · June 17, 2026 · Grant9.4K
- Furey Raymond J. · June 17, 2026 · Grant7.4K
- RODRIGUEZ RAUL R · June 17, 2026 · Grant31.7K
- Santos David A · June 17, 2026 · Grant7.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 15.60M
- Total value held
- $386.22M
- Institutional holders
- 142
- Unknown1.77M
- Unknown1.28M
- Unknown1.12M
- Unknown764.2K
- Unknown666.4K
- Unknown601.5K
- Unknown598.4K
- Unknown544.4K
- Unknown445.7K
- Unknown440.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified
Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.